Clinical Trial Update: A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing trastuzumab emtansine (T-DM1) to trastuzumab as adjuvant therapy in HER2-positive breast cancer with residual disease after preop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Kadcyla (ado-trastuzumab emtansine)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2019-10-01